risk factors
The absolute risk depends on tumour type, stage of disease, administration of chemotherapy and/or hormone therapy, surgical intervention, the presence of an indwelling central venous catheter, age, immobilization and previous history of VTE. The use of bevacizumab increases the risk of developing VTE.
A predictive model, recently validated, is able to discriminate between ambulatory patients with low (score 0), intermediate (score 1 or 2) or high risk (score ‡3) of chemotherapyassociated thrombosis. Five variables have been included: (i) site of cancer: cancer sites at very high risk (stomach, pancreas: risk score 2), high risk (lung, lymphoma, gynaecological, genitourinary: risk score 1) and low risk (breast, colorectal, head and neck: risk score 1); (ii) prechemotherapy platelet count of ‡350 · 10 9 /l (risk score 1); (iii) haemoglobin level <10 g/dl, use of erythropoiesisstimulating agents or both (risk score 1); (iv) leukocyte count >11·10 9 /l (risk score 1); (v) body mass index of ‡35 kg/m 2 (risk score 1). The incidence of VTE is 0.3%, 2% and 6.7% in patients with low-, intermediate-and high-risk score, respectively. This model might be used to identify ambulatory cancer patients who are clinically at high risk for VTE.
The role of hereditary thrombophilia is still unclear. Screening for the most common polymorphisms is therefore not indicated.
diagnosis of VTE in occult malignancy
There is general agreement that patients with idiopathic thrombosis present a higher risk of occult cancer. Part of these malignancies can be identified by routine assessments at the time of the thrombotic event. To date, without definitive data to demonstrate an advantage in terms of overall survival using invasive diagnostic tests and intensive follow-up, patients should undergo only physical examination, faecal occult blood test, chest X-ray, urological visit in men, gynaecological visit in women. The request for more expensive examinations such as computerized tomography (CT) scan, digestive endoscopy or tumour markers should be addressed in the case of a strong clinical suspicion of occult cancer [II, C]. acute treatment: thrombolytic therapy Thrombolytic treatment should be considered for specific subgroups of patients such as those with pulmonary embolism presenting with severe right ventricular dysfunction, and for patients with massive ilio-femoral thrombosis at risk of limb gangrene, where rapid venous decompression and flow restoration may be desirable. Urokinase, streptokinase and tissue-type plasminogen activator are able to achieve a rapid lysis of fresh pulmonary emboli [II, A].
long-term treatment
According to standard treatment, the initial phase is followed by treatment with oral anticoagulation with vitamin K antagonists (VKAs) administered for 3-6 months, at a therapeutic INR range from 2 to 3. VKA is started within 24 h from initiating heparin (UFH or LMWH) administration. A full dose of heparin is continued for at least 5 days and suspended when full anticoagulation by VKA (i.e. INR > 2.0) is achieved for at least 2 consecutive days.
However, oral anticoagulation with VKA may be problematic in patients with cancer. Drug interactions, malnutrition and liver dysfunction can lead to wide fluctuations in INR. Cancer patients have both a higher rate of VTE recurrence during oral anticoagulant therapy with VKA and a higher anticoagulation-associated haemorrhagic risk as compared with non-cancer patients.
Results from recent randomized clinical trials demonstrate that in these patients long-term treatment for 6 months with 75%-80% (i.e. 150 U/kg o.d.) of the initial dose of LMWH is safe and more effective than treatment with VKA. This schedule is recommended for long-term anticoagulant therapy in cancer patients [I, A].
duration of therapy
It is recommended that anticoagulant therapy be continued as long as there is clinical evidence of active malignant disease (e.g. chronic metastatic disease) [III, C] .
anticoagulant therapy in patients with recurrence of VTE Patients adequately anticoagulated who develop VTE recurrence should be checked for progression of their malignancy.
Cancer patients have a threefold risk of recurrent VTE and a threefold to sixfold risk of major bleeding while receiving anticoagulant treatment with a VKA, as compared with patients without cancer.
Patients on long-term anticoagulation with VKA, who develop VTE when INR is in the subtherapeutic range can be retreated with UFH or LMWH until VKA anticoagulation has achieved a stable INR of between 2.0 and 3.0. If VTE recurrence occurs while the INR is in the therapeutic range there are two options: (i) either shift to another method of anticoagulation, such as subcutaneous UFH maintaining a therapeutic aPTT (aPTT ratio of 1.5-2.5), or LMWH at weight-adjusted dose; (ii) or increase the INR (to a target of 3.5). Full-dose LMWH (200 U/kg o.d.) can be resumed in patients with a VTE recurrence while receiving a reduced dose of LMWH or VKA anticoagulation as long-term therapy. Escalating the dose of LMWH results in a second recurrent VTE rate of 9%, it is well tolerated, with few bleeding complications [II, B] .
use of a vena cava filter
The use of an inferior vena cava filter should be considered in patients with recurrent pulmonary embolism despite adequate anticoagulant treatment or with a contraindication to anticoagulant therapy (i.e. active bleeding and profound, prolonged thrombocytopenia). Once the risk of bleeding is reduced, patients with a vena cava filter should receive or resume anticoagulant therapy in order to reduce the risk
